Tyra Biosciences, Inc. TYRA R2K

Healthcare · Biotechnology · United States

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Market & Price

Market Cap

$1.99B

Current Price

$33.41

High / Low (52W)

$39.61 / $9.10

Beta

0.79

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$4.83

Price to Book

6.92

P/S

EV/EBITDA

-11.30

Dividend Yield

Profitability & Returns

ROCE

-50.19%

ROE

-36.87%

ROA

-23.64%

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.64

EPS (TTM)

$-2.18

Balance Sheet & Liquidity

Debt/Equity

1.47

Quick Ratio

20.05

Current Ratio

20.49

Debt

$5.70M

Total Assets

$282.61M

Current Assets

$265.45M

Working Capital

$247.36M

Ownership

Promoter Holding

2.86%

Chg in Prom Hold

FII / Inst Holding

111.40%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.61B

Total Revenue (TTM)

EBITDA

$-142.37M

Free Cash Flow

$-60.14M

Operating Cash Flow

$-102.25M

Shares Outstanding

59.47M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

-38.93%

Revenue (YoY)

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -38.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TYRA Tyra Biosciences, Inc. R2K	33.41	-	$1.99B	-	-50.19%	-36.87%	-	-38.93%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.85M	31.45M	32.94M	36.52M	42.00M
Operating Income	-	-	-2.33M	-	-4.21M	-5.51M	-6.64M	-14.83M	-15.43M	-13.64M	-14.33M	-16.01M	-23.96M	-22.32M	-23.53M	-28.60M	-31.85M	-31.45M	-32.94M	-36.52M	-42.00M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-31.71M	-31.31M	-32.81M	-36.38M	-41.86M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-28.15M	-28.10M	-29.87M	-33.83M	-39.30M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-1.47M	-1.84M	-2.34M	-3.69M	-4.21M	-5.51M	-6.64M	-14.83M	-15.10M	-12.51M	-11.88M	-13.27M	-21.15M	-18.19M	-18.70M	-24.02M	-28.15M	-28.10M	-29.87M	-33.83M	-39.30M
Diluted EPS	-	-	-	-	-	-2.43	-0.72	-0.36	-0.36	-0.30	-0.28	-0.31	-0.49	-0.35	-0.32	-0.41	-0.47	-0.47	-0.50	-0.57	-0.64
R&D Expense	-	-	1.86M	-	3.52M	4.38M	5.48M	9.64M	12.05M	10.91M	10.41M	12.16M	19.27M	17.20M	18.00M	22.70M	24.96M	24.31M	25.47M	-	33.47M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	-	-	58.93M	79.94M	104.18M	132.76M
Operating Income	-9.30M	-	-58.93M	-79.94M	-104.18M	-132.76M
EBITDA	-	-	-58.63M	-79.59M	-103.66M	-132.22M
Interest Expense	-	-	-	-	-	-
Pretax Income	-	-	-55.33M	-69.13M	-86.48M	-119.95M
Tax Provision	-	-	-	-	-	-
Net Income	-9.34M	-	-55.33M	-69.13M	-86.48M	-119.95M
Diluted EPS	-	-1.91	-1.32	-1.62	-1.51	-
R&D Expense	7.20M	20.64M	43.01M	62.52M	80.08M	102.93M

Compounded Sales Growth

5 Years:	-
1 Year:	-

Compounded Profit Growth

5 Years:	-38.93%
1 Year:	-

Stock Price Performance

1 Year:	+267.14%
6 Months:	+52.56%
3 Months:	+0.30%
1 Month:	-1.11%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	16.01M	-	266.18M	225.86M	363.56M	282.61M
Current Assets	-	-	-	257.29M	211.67M	347.46M	265.45M
Cash & Equivalents	-	15.22M	-	251.21M	58.01M	91.97M	77.39M
Inventory	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-
Total Liabilities	-	2.00M	-	8.35M	21.59M	20.41M	23.43M
Current Liabilities	-	1.86M	-	5.70M	15.33M	14.59M	18.09M
Long Term Debt	-	-	-	-	-	-	-
Total Debt	-	-	-	2.62M	6.50M	6.22M	5.81M
Total Equity	-4.74M	-13.64M	-	257.83M	204.26M	343.15M	259.18M
Shares Outstanding	-	-	-	42.35M	43.02M	50.75M	53.71M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-7.76M	-	-50.28M	-50.14M	-69.77M	-95.14M
Investing Cash Flow	-312.00K	-	-559.00K	-144.60M	-98.40M	72.46M
Financing Cash Flow	23.43M	-	632.00K	1.54M	202.14M	8.10M
Capital Expenditure	-312.00K	-	-559.00K	-770.00K	-664.00K	-141.00K
Free Cash Flow	-8.07M	-	-50.84M	-50.91M	-70.44M	-95.28M
Net Change in Cash	-	-	-50.21M	-193.21M	33.96M	-14.58M

Ratios (Annual)

Figures in %.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-
Net Margin %	-	-	-	-	-	-
ROE %	68.5%	-	-21.5%	-33.8%	-25.2%	-46.3%
ROCE %	-65.7%	-	-22.6%	-38.0%	-29.9%	-50.2%

Shareholding Pattern

Insiders

2.86%

Institutions

111.40%

Public Float

114.68%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	RA Capital Management, L.P.	20.51%	12.20M	$407.56M
2	FMR, LLC	13.03%	7.75M	$258.85M
3	Nextech Invest, Ltd.	6.82%	4.06M	$135.51M
4	Janus Henderson Group PLC	6.54%	3.89M	$129.98M
5	Alta Partners Management Company, L.P.	6.43%	3.82M	$127.74M
6	Farallon Capital Management LLC	6.02%	3.58M	$119.64M
7	TCG Crossover Management, LLC	5.46%	3.25M	$108.55M
8	Commodore Capital Lp	4.16%	2.48M	$82.69M
9	Blackrock Inc.	3.73%	2.22M	$74.10M
10	Paradigm Biocapital Advisors LP	3.46%	2.05M	$68.66M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TYRA

No recent headlines available.

TYRA · Healthcare